Medtronic posts 24-month TITAN 2 data showing sustained nocturia reduction with Altaviva device
Bitget2026/10/06 21:01Medtronic disclosed new 24-month exploratory results from the TITAN 2 pivotal trial at the 47th AUGS Annual Scientific Meeting. The analysis showed durable reductions in nightly urination episodes, with sleep-related quality of life improving for many patients. The update supports the clinical profile of Altaviva, an implantable tibial neuromodulation device cleared in September 2025 for urge urinary incontinence. Medtronic also launched the ENDURANCE post-approval study, a five-year, real-world trial tracking 170 implanted patients across up to 30 US centers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Medtronic disclosed new 24-month exploratory results from the TITAN 2 pivotal trial at the 47th AUGS Annual Scientific Meeting.
- The analysis showed durable reductions in nightly urination episodes, with sleep-related quality of life improving for many patients.
- The update supports the clinical profile of Altaviva, an implantable tibial neuromodulation device cleared in September 2025 for urge urinary incontinence.
- Medtronic also launched the ENDURANCE post-approval study, a five-year, real-world trial tracking 170 implanted patients across up to 30 US centers.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wedbush: Hard drive supply falls short of demand, Seagate (STX.US) and Western Digital (WDC.US) earnings reports may bring surprises
Wedbush reiterated its "outperform" ratings for Seagate and Western Digital, setting target prices at $1,000 and $650, respectively.
JPMorgan maintains Underweight rating on Nike (NKE.US): Deep in adjustment pains, performance pressures may persist until fiscal year 2028
Recently, JPMorgan released a U.S. equity research report on Nike. The research team participated in a face-to-face meeting with Nike's new CFO, Denton, updated profit assumptions based on management statements, and maintained an “underweight” investment rating on Nike.
Piper Sandler lowers Meta's target price to $850
Crypto prices
More
